Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?
Author(s)
Vasikasin, Vasin
Rawson, Timothy M
Holmes, Alison H
Otter, Jonathan
Type
Journal Article
Abstract
The emergence of carbapenem-resistant organisms (CROs) is a significant global threat. Reduction of carbapenem consumption can decrease CROs. In the global endemic era of ESBL-producing bacteria, carbapenems are considered the treatment of choice, leading to challenge in limiting carbapenem use. This review describes the role of precision prescribing for prevention of CROs. This involves improving antibiotic selection, dosing and shortening duration. The effect of different antibiotics, dosing and duration on CRO development are explored. Available options for precision prescribing, gaps in the scientific evidence, and areas for future research are also presented.
Date Issued
2023-04
Date Acceptance
2023-03-01
Citation
JAC-Antimicrobial Resistance, 2023, 5 (2), pp.1-13
ISSN
2632-1823
Publisher
Oxford University Press
Start Page
1
End Page
13
Journal / Book Title
JAC-Antimicrobial Resistance
Volume
5
Issue
2
Copyright Statement
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000959589600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
Subjects
ACINETOBACTER-BAUMANNII
ANTIMICROBIAL THERAPY
BETA-LACTAM
BLOOD-STREAM INFECTIONS
CRITICALLY-ILL PATIENTS
EMPIRIC THERAPY
Infectious Diseases
INTENSIVE-CARE-UNIT
Life Sciences & Biomedicine
Microbiology
MULTIDRUG-RESISTANT
Pharmacology & Pharmacy
PSEUDOMONAS-AERUGINOSA
Science & Technology
STEWARDSHIP PROGRAM
Publication Status
Published
Article Number
dlad036
Date Publish Online
2023-03-29